DIA, together with the US Food and Drug Administration (US FDA), and in collaboration with Society for Clinical Trials, will host DIA/FDA: Revitalizing Productivity in Drug Development in Bethesda, Maryland on October 23-24.

This two-day conference will evaluate the status quo and the current initiatives and challenges of the pharmaceutical industry and R&D productivity in drug development with open discussions and review panels. DIA is the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide.

Session topics include designing efficient clinical programmes, enrichment of clinical study populations, improving clinical research’s efficiency and quality, leveraging biomarker data, and more.

“Keynote addresses by our informative, dynamic speakers will add value and significance to this meeting while attendees learn and create solutions. This meeting’s sessions will create a forum for those to network, share thoughts on research and create solutions, visions and perspectives, and discuss upcoming initiatives to improve efficiency,” says Program Chairperson H. M. James Hung, director, Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, CDER, FDA. “Drug development is ever-changing and we wish to offer the tools needed.”

For further details contact: Christine Tarlecki,  DIA, Christine.Tarlecki@diahome.org